APHB:NYE-AmpliPhi Biosciences Corporation (USD)

COMMON STOCK | Other | NYE

Last Closing Price

USD 0.12

Change

0.00 (0.00)%

Market Cap

USD 0.15B

Volume

1.67M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

As of May 9, 2019, was acquired by C3J Therapeutics, Inc., in a reverse merger transaction.

Company Website : http://www.ampliphibio.com

Address : 3579 Valley Centre Drive, Suite 100 92130,San Diego,USA

Employees : 30

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 0.15

52 Week Low : 0.06

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BMS Bemis Company, Inc

N/A

 USD370,676,430.93B 1,000,000.00 N/A
NAO Nordic American Offshore Ltd

N/A

 USD387,070.41B N/A N/A
ITC ITC Holdings Corp

N/A

 USD3,166.52B 22.84 N/A
USB-PA U.S. Bancorp PERP PFD SER A

N/A

 USD1,536.23B 206.60 N/A
MSF Morgan Stanley Emerging Market..

N/A

 USD1,000.65B 24.60 N/A
HSBC-PA HSBC Holdings plc ADR A 1/40PF..

N/A

 USD544.02B 1,677.50 N/A
SAN-PB Banco Santander, S.A. GTD PFD ..

N/A

 USD384.20B 46.00 N/A
BAC-PW Bank of America Corporation

N/A

 USD267.69B 9.46 N/A
BAC-PY Bank of America Corporation

N/A

 USD263.53B 9.36 N/A
BEL Belmond Ltd

N/A

 USD261.58B 15.94 N/A

ETFs Containing APHB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.15B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -15.88 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -126.70% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.